These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 20592198)

  • 1. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.
    Bianchi P; Ciani E; Guidi S; Trazzi S; Felice D; Grossi G; Fernandez M; Giuliani A; Calzà L; Bartesaghi R
    J Neurosci; 2010 Jun; 30(26):8769-79. PubMed ID: 20592198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome.
    Guidi S; Stagni F; Bianchi P; Ciani E; Ragazzi E; Trazzi S; Grossi G; Mangano C; Calzà L; Bartesaghi R
    Brain Pathol; 2013 Mar; 23(2):129-43. PubMed ID: 22817700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
    Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
    Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.
    Guidi S; Stagni F; Bianchi P; Ciani E; Giacomini A; De Franceschi M; Moldrich R; Kurniawan N; Mardon K; Giuliani A; Calzà L; Bartesaghi R
    Brain; 2014 Feb; 137(Pt 2):380-401. PubMed ID: 24334313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome.
    Stagni F; Magistretti J; Guidi S; Ciani E; Mangano C; Calzà L; Bartesaghi R
    PLoS One; 2013; 8(4):e61689. PubMed ID: 23620781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
    Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
    Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome.
    Stagni F; Uguagliati B; Emili M; Giacomini A; Bartesaghi R; Guidi S
    Sci Rep; 2021 Mar; 11(1):6300. PubMed ID: 33737521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome.
    Emili M; Stagni F; Salvalai ME; Uguagliati B; Giacomini A; Albac C; Potier MC; Grilli M; Bartesaghi R; Guidi S
    Neurobiol Dis; 2020 Jul; 140():104874. PubMed ID: 32325119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome.
    Stagni F; Salvalai ME; Giacomini A; Emili M; Uguagliati B; Xia E; Grilli M; Bartesaghi R; Guidi S
    Neurobiol Dis; 2019 Sep; 129():44-55. PubMed ID: 31085229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Raspanti A; Giacomini A; Guidi S; Emili M; Ciani E; Giuliani A; Bighinati A; Calzà L; Magistretti J; Bartesaghi R
    Neurobiol Dis; 2017 Jul; 103():11-23. PubMed ID: 28359846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome.
    Clark S; Schwalbe J; Stasko MR; Yarowsky PJ; Costa AC
    Exp Neurol; 2006 Jul; 200(1):256-61. PubMed ID: 16624293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome.
    Giacomini A; Stagni F; Trazzi S; Guidi S; Emili M; Brigham E; Ciani E; Bartesaghi R
    Neurobiol Dis; 2015 Oct; 82():385-396. PubMed ID: 26254735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome.
    Guidi S; Bianchi P; Stagni F; Giacomini A; Emili M; Trazzi S; Ciani E; Bartesaghi R
    CNS Neurol Disord Drug Targets; 2017; 16(7):812-819. PubMed ID: 27488422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
    Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
    Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model.
    Kohl Z; Winner B; Ubhi K; Rockenstein E; Mante M; Münch M; Barlow C; Carter T; Masliah E; Winkler J
    Eur J Neurosci; 2012 Jan; 35(1):10-9. PubMed ID: 22211740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.
    Heinen M; Hettich MM; Ryan DP; Schnell S; Paesler K; Ehninger D
    Neural Plast; 2012; 2012():467251. PubMed ID: 22848851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome.
    Uguagliati B; Al-Absi AR; Stagni F; Emili M; Giacomini A; Guidi S; Nyengaard JR; Bartesaghi R
    Hippocampus; 2021 Apr; 31(4):435-447. PubMed ID: 33464704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome.
    Trazzi S; Fuchs C; De Franceschi M; Mitrugno VM; Bartesaghi R; Ciani E
    Neurobiol Dis; 2014 Jul; 67():24-36. PubMed ID: 24636797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.
    Velazquez R; Ash JA; Powers BE; Kelley CM; Strawderman M; Luscher ZI; Ginsberg SD; Mufson EJ; Strupp BJ
    Neurobiol Dis; 2013 Oct; 58():92-101. PubMed ID: 23643842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.